Define Fit-for-Purpose Donors for Next-Generation Cell Therapies
Donor biology can influence therapeutic performance, manufacturability, and the long-term success of allogeneic cell therapy platforms.
The 4th Donor Selection & Cell Source Summit offers a unique opportunity for translational scientists, discovery teams, and cell therapy developers to explore how donor selection can drive stronger clinical and manufacturing outcomes.
Why Attend?
Learn how innovators are:
Defining donor profiles that improve clinical performance
Identifying donor traits that drive desirable cell phenotypes
Using donor insights to strengthen platform development decisions
Applying donor characterisation to accelerate candidate optimisation
Reducing early variability to improve development success
Building donor strategies that support future platform expansion
Leave With Insights On:
- Donor biology factors that influence therapeutic performance
- Emerging selection approaches that improve donor quality
- Donor strategies that strengthen translational success
- Early donor insights that de-risk development programmes
Explore the Full Event Guide
- Discover donor selection strategies from Cellectis, Mesoblast, Atara Bio, and Caribou Bio to improve clinical outcomes
- Explore donor sourcing from cord blood, PBMCs, and iPSCs to benchmark strategies, and gain clarity on where the field is moving
- Review the full agenda, speakers, and sessions to align team priorities
- Identify valuable networking opportunities to maximize connections with peers and providers